1 Biotech Going International

1 Biotech Going International

The shares of orphan drugmaker Raptor Pharmaceuticals have been on a tear since the FDA approval of its nephropathic cystinosis drug Procysbi. Year to date, shares are up more than 140%, and investors heard more good news last week after the drug won approval in the EU. In the following video, from the Motley Fool's health-care show Market Checkup, analysts discuss what this decision means for Raptor investors.

More compelling companies
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

The article 1 Biotech Going International originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published